Cancer cell · 2026
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Zi-Ming, Zhou Zhen, He Zhi-Yong, Han Liang, Fang Jian, Sun Hong-Mei, Liu Hai-Feng, Wang Ming-Xia, Liu Yi-Bing, Qu Xiu-Juan, Yao Yu, Gong Yi, Yu Yan, Shi Hua-Qiu, Wang Yan, Su Chun-Xia, Yang Kun-Yu, Shang Yan-Hong, Ruan Jian, Yuan Xiang-Lin, Zhang Ming-Jun, Luo Hui, Cui Jiu-Wei, Lin Xiao-Yan, Li Meng-Xia, Lou Hai-Zhou, Yang Run-Xiang, Wu Hao, Wang Xi-Cheng, Dan Mo, Zhang Li-Qiong, Su Yang-Zhi, Wan Xue-Chao, Zou Kai, Yang Ying-Ying, Lu Shun
Аннотация
SYS6010 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR). We report the results of a phase 1 trial (ChiCTR2300072141) of SYS6010 in patients with non-small cell lung cancer (NSCLC). A total of 236 patients were treated. One dose-limiting toxicity occurred at 6.4 mg/kg; therefore, 4.2, 4.5, and 4.8 mg/kg were selected for cohort expansion. Treatment-related adverse events (TRAEs; any/grade ≥ 3) occurred in 99.6%/57.2% of patients. Common grade ≥3 TRAEs included neutropenia (30.9%), leukopenia (25.0%), and thrombocytopenia (17.4%). Objective response rate was 34.7% in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs) and platinum chemotherapy, 45.7% in EGFR-mutant NSCLC treated with EGFR TKIs, 20.0% in EGFR wild-type squamous NSCLC, and 35.7% in EGFR wild-type non-squamous NSCLC. Median progression-free survival and overall survival were 7.6 and 19.4 months, respectively, in EGFR-mutant NSCLC treated with EGFR TKIs and platinum chemotherapy. Overall, SYS6010 shows a manageable safety profile and encouraging antitumor activity in previously treated, advanced NSCLC.